BDTX Black Diamond Therapeutics Inc

Price (delayed)

$1.9

Market cap

$109.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.75

Enterprise value

$102.23M

?
Relative Growth: Rel. Growth: 1
Relative Strength: Rel. Strength: 34
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies. Black Diamond is addressing the significant unmet need for novel precision oncology therapies for ...

Highlights
The debt has declined by 23% year-on-year and by 7% since the previous quarter
Black Diamond Therapeutics's EPS has increased by 2.6% QoQ
Black Diamond Therapeutics's gross profit has shrunk by 100% YoY
The revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of BDTX

BDTX stock price

How has the Black Diamond Therapeutics stock price performed over time
Intraday
-4.04%
1 week
-2.06%
1 month
-14.03%
1 year
-40.06%
YTD
-21.81%
QTD
2.7%

Financial performance

How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.9M
Net income
-$42.56M
Gross margin
N/A
Net margin
N/A
Black Diamond Therapeutics's gross profit has shrunk by 100% YoY
The revenue has dropped by 100% year-on-year
BDTX's operating income is up by 2.6% QoQ

Price vs fundamentals

How does BDTX's price correlate with its fundamentals

Growth

What is Black Diamond Therapeutics's growth rate over time

Valuation

What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
1.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Black Diamond Therapeutics's EPS has increased by 2.6% QoQ
The company's equity fell by 28% YoY and by 8% QoQ
The P/B is 9% lower than the 5-year quarterly average of 1.3 and 9% lower than the last 4 quarters average of 1.3
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Black Diamond Therapeutics business performance
Black Diamond Therapeutics's ROE has decreased by 7% from the previous quarter
BDTX's return on invested capital is down by 6% since the previous quarter
The ROA fell by 6% QoQ

Dividends

What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BDTX.

Financial health

How did Black Diamond Therapeutics financials performed over time
Black Diamond Therapeutics's total assets has decreased by 25% YoY and by 6% from the previous quarter
The quick ratio has contracted by 18% YoY and by 14% from the previous quarter
The debt is 86% smaller than the equity
The company's equity fell by 28% YoY and by 8% QoQ
The debt has declined by 23% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.